AACR SPECIAL CONFERENCE IN CANCER RESEARCH: PANCREATIC CANCER
Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in and ongoing Phase 1/2 AD study
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) PDF
PEGS Boston 2023. Native complex membrane antigen expression on poxvirus for antibody discovery
ASCO Poster - PDAC study abstract # TPS4195
AAIC Advancements: Immunity Presentation